美国血液学会2025年指南:老年新诊断急性髓系白血病的治疗
美国血液学会(ASH)组建多学科指南小组,采用推荐分级的评估、制定与评价(GRADE)方法,针对老年急性髓系白血病(AML)患者的管理形成9条关键临床推荐,涵盖是否抗白血病治疗、诱导与缓解后方案选择、维奈克拉联合方案、靶向治疗、造血干细胞移植及输血支持。
要点
- 推荐抗白血病治疗优于最佳支持治疗。
- 推荐基于维奈克拉的方案优于单药治疗。
- 推荐将FLT3抑制剂纳入传统诱导和缓解后治疗。
核心结论
- 关键推荐包括:抗白血病治疗优于最佳支持治疗;基于维奈克拉的方案优于单药治疗;将FLT3抑制剂纳入传统诱导和缓解后治疗。
研究设计与样本
- ASH组建多学科指南小组(包括患者代表),由麦克马斯特大学Clarity Research Group支持系统证据评价,采用GRADE方法及证据到决策框架制定推荐。
主要发现
- 小组就老年AML管理的9条关键临床推荐达成一致,涵盖抗白血病治疗与最佳支持治疗的选择、传统诱导和缓解后治疗与低甲基化药物或低剂量阿糖胞苷或维奈克拉联合方案的比较、缓解后治疗的作用和持续时间、维奈克拉联合方案与单药治疗、靶向治疗(包括异柠檬酸脱氢酶和FMS样酪氨酸激酶3(FLT3)抑制剂)的适用患者、造血干细胞移植在非预后良好AML中的作用以及不再接受抗白血病治疗患者的输血支持。
关键数值与推荐
- 9条关键临床推荐:抗白血病治疗优于最佳支持治疗。
- 基于维奈克拉的方案优于单药治疗。
- 将FLT3抑制剂纳入传统诱导和缓解后治疗。
临床怎么用
- 原文未据此给出具体临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults with acute myeloid leukemia (AML) represent a cancer population in which disease-based risk factors, comorbidities, patient goals, and treatment risks and benefits influence treatment recommendations. OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health professionals in their decisions about management of AML in older adults. METHODS: ASH formed a multidisciplinary guideline panel, including patient representatives, that minimized bias from conflicts of interest. Clarity Research Group at McMaster University supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized questions and outcomes according to their importance for clinicians and patients. The panel used the grading of recommendations assessment, development and evaluation approach, including evidence-to-decision frameworks, to assess evidence and make recommendations. RESULTS: The panel agreed on 9 critical clinical recommendations for managing AML in older adults, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management; traditional induction and postremission therapy vs hypomethylating agent or low-dose cytarabine, or combinations with venetoclax; the role and duration of postremission therapy; combinations with venetoclax vs monotherapy; the use of targeted therapy, including isocitrate dehydrogenase and FMS-like tyrosine kinase 3 (FLT3) inhibitors, in appropriate patients; the role of hematopoietic stem cell transplantation in nonfavorable prognosis AML; and the role of transfusion support for patients no longer receiving antileukemic therapy. CONCLUSIONS: Key recommendations of these guidelines include treatment over best supportive care; venetoclax-based regimens over monotherapies; and incorporation of FLT3 inhibitors into traditional induction and postremission therapy.
引用
- Sekeres MA, Mattison R, Artz A, et al. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2026. PMID: 41321225. doi:10.1182/bloodadvances.2025017934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。